Susquehanna International Group’s NewAmsterdam Pharma NAMS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$571K Sell
17,825
-177,810
-91% -$5.79M ﹤0.01% 9326
2025
Q4
$6.86M Buy
195,635
+43,798
+29% +$1.59M ﹤0.01% 3560
2025
Q3
$4.32M Buy
151,837
+62,010
+69% +$1.49M ﹤0.01% 4326
2025
Q2
$1.63M Sell
89,827
-59,209
-40% -$1.08M ﹤0.01% 6236
2025
Q1
$3.05M Buy
149,036
+140,070
+1,562% +$3.11M ﹤0.01% 4611
2024
Q4
$230K Buy
+8,966
New +$190K ﹤0.01% 10400

Other funds holding NAMS

Susquehanna International Group's NAMS Position: Q1 2026 in Review

Susquehanna International Group reduced its NewAmsterdam Pharma (NAMS) stake by 91% in Q1 2026, selling an estimated $5.79M and leaving 17,825 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #9326.

Susquehanna International Group first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.86M in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Susquehanna International Group held 17,825 shares of NewAmsterdam Pharma worth $571K as of Q1 2026.
  • Susquehanna International Group sold 177,810 NewAmsterdam Pharma shares in Q1 2026, an estimated $5.79M.
  • NewAmsterdam Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9326 holding.
  • Susquehanna International Group first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
  • Susquehanna International Group's NewAmsterdam Pharma position peaked at $6.86M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.